Medexus Net Debt vs Net Receivables Analysis

MDP Stock

2.66 0.08 2.92%

Medexus Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Medexus Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Medexus Pharmaceuticals is a good investment. Please check the relationship between Medexus Pharmaceuticals Net Debt and its Net Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medexus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Debt vs Net Receivables

Net Debt vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Medexus Pharmaceuticals Net Debt account and Net Receivables. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Medexus Pharmaceuticals' Net Debt and Net Receivables is 0.91. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Medexus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Medexus Pharmaceuticals' Net Debt and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Medexus Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Debt i.e., Medexus Pharmaceuticals' Net Debt and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.91

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Net Receivables

Most indicators from Medexus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Medexus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medexus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 2nd of August 2025, Selling General Administrative is likely to grow to about 45.3 M, while Tax Provision is likely to drop (847.4 K).

	2022	2023	2024	2025 (projected)
Gross Profit	60.0M	59.5M	56.6M	28.9M
Total Revenue	108.1M	113.1M	108.3M	113.7M

Gross Profit Total Revenue

Medexus Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Short Term Debt	Intangible Assets	Other Assets	Non Currrent Assets Other	Common Stock
Total Assets		0.93	0.88	0.78	-0.94	0.75	0.75	0.27	0.32	0.94	0.98	0.92	0.39	0.88	0.85	0.85	0.95	0.91	0.83	0.93	0.73	0.55	0.94	0.81	0.83	0.94
Total Current Liabilities	0.93		0.9	0.69	-0.88	0.72	0.72	0.29	0.27	0.8	0.96	0.85	0.08	0.7	0.95	0.67	0.8	0.78	0.58	0.98	0.52	0.5	0.79	0.94	0.96	0.89
Total Stockholder Equity	0.88	0.9		0.43	-0.75	0.85	0.85	0.32	0.25	0.69	0.91	0.69	0.17	0.65	0.86	0.52	0.74	0.65	0.52	0.91	0.42	0.19	0.72	0.85	0.86	0.82
Net Debt	0.78	0.69	0.43		-0.8	0.23	0.23	0.13	0.28	0.88	0.73	0.9	0.36	0.84	0.58	0.85	0.84	0.91	0.8	0.69	0.83	0.87	0.83	0.55	0.6	0.72
Retained Earnings	-0.94	-0.88	-0.75	-0.8		-0.68	-0.68	-0.32	-0.36	-0.92	-0.93	-0.92	-0.26	-0.81	-0.84	-0.85	-0.9	-0.88	-0.79	-0.89	-0.7	-0.6	-0.89	-0.78	-0.78	-0.93
Cash	0.75	0.72	0.85	0.23	-0.68		1.0	0.31	0.28	0.59	0.78	0.56	0.24	0.54	0.67	0.51	0.63	0.5	0.52	0.68	0.35	0.12	0.63	0.63	0.63	0.72
Cash And Short Term Investments	0.75	0.72	0.85	0.23	-0.68	1.0		0.31	0.28	0.59	0.78	0.56	0.24	0.54	0.67	0.51	0.63	0.5	0.52	0.68	0.35	0.12	0.63	0.63	0.63	0.72
Common Stock Shares Outstanding	0.27	0.29	0.32	0.13	-0.32	0.31	0.31		0.69	0.25	0.31	0.26	-0.03	0.19	0.29	0.18	0.24	0.23	0.12	0.29	0.13	0.13	0.23	0.28	0.28	0.3
Other Stockholder Equity	0.32	0.27	0.25	0.28	-0.36	0.28	0.28	0.69		0.33	0.33	0.32	0.12	0.31	0.25	0.32	0.31	0.35	0.31	0.26	0.34	0.3	0.31	0.23	0.24	0.28
Total Liab	0.94	0.8	0.69	0.88	-0.92	0.59	0.59	0.25	0.33		0.89	0.98	0.5	0.93	0.7	0.92	0.99	0.97	0.9	0.81	0.85	0.7	0.99	0.65	0.68	0.93
Total Current Assets	0.98	0.96	0.91	0.73	-0.93	0.78	0.78	0.31	0.33	0.89		0.89	0.27	0.8	0.91	0.77	0.9	0.88	0.74	0.96	0.68	0.53	0.88	0.89	0.9	0.94
Short Long Term Debt Total	0.92	0.85	0.69	0.9	-0.92	0.56	0.56	0.26	0.32	0.98	0.89		0.37	0.9	0.74	0.88	0.96	0.94	0.81	0.83	0.8	0.75	0.95	0.71	0.74	0.93
Other Current Liab	0.39	0.08	0.17	0.36	-0.26	0.24	0.24	-0.03	0.12	0.5	0.27	0.37		0.59	-0.08	0.63	0.54	0.49	0.73	0.09	0.58	0.25	0.57	-0.14	-0.07	0.25
Property Plant And Equipment Net	0.88	0.7	0.65	0.84	-0.81	0.54	0.54	0.19	0.31	0.93	0.8	0.9	0.59		0.54	0.9	0.96	0.88	0.92	0.72	0.82	0.63	0.97	0.48	0.53	0.81
Current Deferred Revenue	0.85	0.95	0.86	0.58	-0.84	0.67	0.67	0.29	0.25	0.7	0.91	0.74	-0.08	0.54		0.56	0.69	0.71	0.46	0.96	0.42	0.36	0.67	0.98	0.96	0.86
Accounts Payable	0.85	0.67	0.52	0.85	-0.85	0.51	0.51	0.18	0.32	0.92	0.77	0.88	0.63	0.9	0.56		0.92	0.89	0.96	0.67	0.79	0.66	0.93	0.47	0.49	0.78
Non Current Assets Total	0.95	0.8	0.74	0.84	-0.9	0.63	0.63	0.24	0.31	0.99	0.9	0.96	0.54	0.96	0.69	0.92		0.94	0.9	0.82	0.82	0.63	1.0	0.64	0.67	0.93
Net Receivables	0.91	0.78	0.65	0.91	-0.88	0.5	0.5	0.23	0.35	0.97	0.88	0.94	0.49	0.88	0.71	0.89	0.94		0.88	0.79	0.91	0.75	0.94	0.68	0.71	0.87
Non Current Liabilities Total	0.83	0.58	0.52	0.8	-0.79	0.52	0.52	0.12	0.31	0.9	0.74	0.81	0.73	0.92	0.46	0.96	0.9	0.88		0.61	0.87	0.6	0.92	0.38	0.41	0.73
Inventory	0.93	0.98	0.91	0.69	-0.89	0.68	0.68	0.29	0.26	0.81	0.96	0.83	0.09	0.72	0.96	0.67	0.82	0.79	0.61		0.53	0.42	0.8	0.93	0.94	0.91
Other Current Assets	0.73	0.52	0.42	0.83	-0.7	0.35	0.35	0.13	0.34	0.85	0.68	0.8	0.58	0.82	0.42	0.79	0.82	0.91	0.87	0.53		0.79	0.82	0.41	0.46	0.68
Short Term Debt	0.55	0.5	0.19	0.87	-0.6	0.12	0.12	0.13	0.3	0.7	0.53	0.75	0.25	0.63	0.36	0.66	0.63	0.75	0.6	0.42	0.79		0.62	0.39	0.45	0.51
Intangible Assets	0.94	0.79	0.72	0.83	-0.89	0.63	0.63	0.23	0.31	0.99	0.88	0.95	0.57	0.97	0.67	0.93	1.0	0.94	0.92	0.8	0.82	0.62		0.6	0.64	0.91
Other Assets	0.81	0.94	0.85	0.55	-0.78	0.63	0.63	0.28	0.23	0.65	0.89	0.71	-0.14	0.48	0.98	0.47	0.64	0.68	0.38	0.93	0.41	0.39	0.6		0.99	0.81
Non Currrent Assets Other	0.83	0.96	0.86	0.6	-0.78	0.63	0.63	0.28	0.24	0.68	0.9	0.74	-0.07	0.53	0.96	0.49	0.67	0.71	0.41	0.94	0.46	0.45	0.64	0.99		0.81
Common Stock	0.94	0.89	0.82	0.72	-0.93	0.72	0.72	0.3	0.28	0.93	0.94	0.93	0.25	0.81	0.86	0.78	0.93	0.87	0.73	0.91	0.68	0.51	0.91	0.81	0.81

Click cells to compare fundamentals

Medexus Pharmaceuticals Account Relationship Matchups

Medexus Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	148.5M	139.2M	161.3M	155.7M	171.8M	180.4M
Total Current Liabilities	39.9M	48.1M	83.5M	66.2M	97.3M	102.2M
Total Stockholder Equity	18.0M	17.8M	22.4M	30.3M	52.1M	54.8M
Net Debt	26.2M	44.8M	57.0M	44.6M	13.2M	16.1M
Retained Earnings	(62.4M)	(65.2M)	(64.0M)	(64.2M)	(62.0M)	(58.9M)
Cash	18.7M	10.0M	13.1M	5.3M	24.0M	25.2M
Cash And Short Term Investments	18.7M	10.0M	13.1M	5.3M	24.0M	25.2M
Common Stock Shares Outstanding	15.2M	19.9M	20.5M	22.5M	32.3M	17.9M
Liabilities And Stockholders Equity	148.5M	139.2M	161.3M	155.7M	171.8M	180.4M
Other Stockholder Equity	9.5M	10.4M	11.3M	12.0M	6.0M	7.6M
Total Liab	130.5M	121.4M	138.9M	125.4M	119.7M	63.6M
Total Current Assets	58.6M	49.1M	73.0M	72.5M	80.6M	84.6M
Short Long Term Debt Total	44.9M	54.9M	70.1M	49.9M	57.4M	28.8M
Other Current Liab	14.5M	2.6M	2.7M	2.7M	125K	118.8K
Property Plant And Equipment Net	795K	1.2M	899K	778K	689K	574.1K
Accounts Payable	14.9M	12.0M	10.2M	7.8M	5.7M	6.5M
Non Current Assets Total	89.9M	90.1M	88.4M	83.2M	91.3M	53.4M
Net Receivables	18.8M	14.4M	22.4M	24.0M	13.2M	10.7M
Non Current Liabilities Total	90.6M	73.3M	55.4M	59.2M	22.4M	38.9M
Inventory	14.7M	21.4M	22.8M	30.8M	35.3M	37.1M
Other Current Assets	1.7M	1.3M	2.3M	2.3M	376K	357.2K
Intangible Assets	76.4M	76.6M	70.4M	64.1M	71.6M	43.7M
Other Assets	2.1M	1.6M	6.8M	8.0M	9.0M	9.4M
Non Currrent Assets Other	2.1M	2.1M	1.6M	9.2M	10.6M	11.1M
Common Stock	66.7M	68.7M	69.0M	76.4M	96.1M	58.6M
Long Term Debt	34.3M	39.8M	27.4M	34.2M	198K	188.1K
Long Term Debt Total	34.3M	39.8M	27.4M	34.2M	198K	188.1K
Capital Surpluse	9.5M	10.4M	11.3M	12.0M	12.0M	9.5M
Cash And Equivalents	18.7M	10.0M	13.1M	5.3M	24.0M	12.7M
Property Plant Equipment	795K	1.2M	899K	778K	689K	780.4K
Net Tangible Assets	(55.5M)	(69.0M)	(69.5M)	(58.2M)	(52.4M)	(55.0M)
Net Invested Capital	62.9M	72.7M	92.5M	80.2M	89.3M	70.3M
Short Long Term Debt	10.6M	15.0M	42.7M	15.7M	37.0M	20.6M
Net Working Capital	18.6M	1.0M	(10.5M)	6.3M	(16.7M)	(15.9M)
Other Liab	35.7M	56.3M	33.5M	28.0M	25.2M	30.9M
Good Will	10.7M	10.7M	10.3M	10.3M	10.0M	10.8M
Accumulated Other Comprehensive Income	4.2M	4.0M	6.2M	6.2M	7.1M	4.6M
Capital Stock	66.7M	68.7M	69.0M	76.4M	96.1M	73.1M

Pair Trading with Medexus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Medexus Stock

0.43	WEF	Western Forest Products Earnings Call This Week	Pair Corr
0.39	IGM	IGM Financial Earnings Call This Week	Pair Corr
0.37	BRK	Berkshire Hathaway CDR	Pair Corr
0.31	AAPL	Apple Inc CDR	Pair Corr

The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.

The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medexus Stock

Balance Sheet is a snapshot of the financial position of Medexus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Medexus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Medexus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Medexus currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Medexus Net Debt vs Net Receivables Analysis

Net Debt vs Net Receivables

Net Debt vs Net Receivables Correlation Analysis

Correlation Coefficient

Net Debt

Net Receivables

Medexus Pharmaceuticals fundamental ratios Correlations

Medexus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medexus Pharmaceuticals fundamental ratios Accounts

Pair Trading with Medexus Pharmaceuticals

Moving against Medexus Stock

Other Information on Investing in Medexus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Intangible Assets	+ 1.0	Non Current Assets Total
Non Current Assets Total	+ 0.99	Total Liab
Intangible Assets	+ 0.99	Total Liab
Non Currrent Assets Other	+ 0.99	Other Assets
Total Current Assets	+ 0.98	Total Assets

Retained Earnings	- 0.94	Total Assets
Common Stock	- 0.93	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings
Short Long Term Debt Total	- 0.92	Retained Earnings
Total Liab	- 0.92	Retained Earnings
Non Current Assets Total	- 0.9	Retained Earnings